Proactive Investors - Run By Investors For Investors

Lancor Scientific on the commercial push as it advances its tumour trace product

Lancor Scientific's CEO Aamir Butt and sales director Rory Lavelle update Proactive London's Andrew Scott on developments as news broke that they've gained access to a cancer research laboratory in Austria. 

''Having access to that kind of capability means we can now make the bold claim that by the end of 2019 we'll have a device capable of multiple cancers'', Butt says.

''What we're aiming to do is make cancer detection available for everyone, everywhere'', he adds.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here  
View full LANCO profile View Profile

Lancor Scientific Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use